Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics-Reference-Cited by-同舟云学术

Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics

Published:2023-11-18 Issue: Volume: Page:
ISSN:2191-1630
Container-title:BioNanoScience
language:en
Short-container-title:BioNanoSci.

Author:

Tiwary Neha,Sharma Neelam,Singh Sukhbir,Behl Tapan,Zahoor Ishrat

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Bioengineering

Link

https://link.springer.com/content/pdf/10.1007/s12668-023-01234-7.pdf

Reference145 articles.

1. Kaul, K., Tarr, J.M., Ahmad, S.I., Kohner, E.M., & Chibber, R. (2013). Introduction to diabetes mellitus. In S. I. Ahmad (Ed.), Diabetes. Advances in Experimental Medicine and Biology (vol. 771). Springer.

2. Grewal, A. S., Thapa, K., Kanojia, N., Sharma, N., & Singh, S. (2020). Natural compounds as source of aldose reductase (Ar) inhibitors for the treatment of diabetic complications: A mini review. Current Drug Metabolism, 21(14), 1091–1116.

3. Andukuri, R., Drincic, A., & Rendell, M. (2009). Alogliptin: A new addition to the class of DPP-4 inhibitors. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2, 117–126.

4. Forouhi, N. G., & Wareham, N. J. (2010). Epidemiology of diabetes. Medicine, 38(11), 602–606.

5. Mayer-Davis, E. J., Kahkoska, A. R., Jefferies, C., Dabelea, D., Balde, N., Gong, C. X., Aschner, P., & Craig, M. E. (2018). ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatric Diabetes, 19(Suppl 27), 7–19.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supervised Machine Learning-Based Models for Predicting Raised Blood Sugar;International Journal of Environmental Research and Public Health;2024-06-27